A new type of treatment for osteoarthritis, currently in canine clinical trials, shows promise for eventual use in humans.
The treatment, developed by Cornell biomedical engineers, is a synthetic version of a naturally occurring joint lubricant that binds to the surface of cartilage in joints and acts as a cushion during high-impact activities, such as running.
“When the production of that specific lubricant goes down, it creates higher contact between the surfaces of the joint and, over time, it leads to osteoarthritis,” said David Putnam, a professor in the College of Engineering with appointments in the Meinig School of Biomedical Engineering and the Smith School of Chemical and Biomolecular Engineering.
Putnam is senior author of “Boundary Mode Lubrication of Articular Cartilage With a Biomimetic Diblock Copolymer,” published June 4 in Proceedings of the National Academy of Sciences, USA. Zhexun Sun, a postdoctoral researcher in Putnam’s lab, is the paper’s first author.
The study focuses on a naturally occurring joint lubricant called lubricin, the production of which declines following traumatic injuries to a joint, such as a ligament tear in a knee.
The knee is lubricated in two ways – hydrodynamic mode and boundary mode.
Hydrodynamic mode lubrication occurs when the joint is moving fast and there isn’t a strong force pushing down on it. In this mode, joints are lubricated by compounds like hyaluronic acid (HA) that are thick and gooey, like car oil. There are numerous HA products on the market, approved by the Food and Drug Administration, for treating hydrodynamic mode lubrication disorders.
But HA is ineffective when strong forces are pushing down on the joint, such as those that occur during running or jumping. In these instances, thick gooey HA squirts out from between the cartilage surfaces, and boundary mode lubrication is necessary. Under these forces, lubricin binds to the surface of the cartilage. It contains sugars that hold on to water, to cushion hard forces on the knee.
In the paper, the researchers describe a synthetic polymer they developed that mimics the function of lubricin and is much easier to produce. “We are in clinical trials, with dogs that have osteoarthritis, with our collaborators at Cornell’s College of Veterinary Medicine,” Putnam said.
Those collaborators – Ursula Krotscheck and Kei Hayashi, both associate professors in the Section of Small Animal Surgery in the Department of Clinical Sciences – use a force plate to measure the efficacy of the treatments. The force plate quantifies the amount of force that a dog exerts with each paw, to measure whether they are favoring one paw over another.
“Once we finalize the efficacy study in dogs, we will be in a very good position to market the material for veterinary osteoarthritis treatment,” Putnam said. From there, the human market for a lubricin substitute should follow, just as HA has been made available for human use, mainly in knees.
The Latest on: Osteoarthritis
via Google News
The Latest on: Osteoarthritis
- With clinical focus elsewhere, Germany's Merck sells off osteoarthritis drug to Novartison October 7, 2020 at 4:10 am
Germany’s Merck is pretty busy with its focus on cancer (notably its Pfizer-partnered Bavencio) and neurology, so it' ...
- Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritison October 6, 2020 at 2:30 pm
Merck, a leading science and technology company, today announced that it has entered into an out-licensing agreement with Novartis, for ...
- Novartis nabs osteoarthritis candidate from Germany's Merckon October 6, 2020 at 11:04 am
Novartis (NVS -1.4%) has in-licensed exclusive global rights to a Phase 2-ready program in osteoarthritis, M6495, from Merck KGaA (OTCPK:MKGAY).The candidate, an anti-ADAMTS5 (a disintegrin and ...
- Machine learning detects early signs of osteoarthritison October 6, 2020 at 10:32 am
Using artificial intelligence and MRI scans, researchers identified signs of osteoarthritis three years before diagnosis.
- Merck KGaA to Outlicense Osteoarthritis Clinical Program for Up to EUR450 Millionon October 6, 2020 at 5:55 am
Global News Select Merck KGaA to Outlicense Osteoarthritis Clinical Program for Up to EUR450 Million . Provided by Dow Jones. Oct 6, 2020 12:55 PM UTC ...
- Machine learning algorithm could help detect osteoarthritis years before symptoms appearon October 5, 2020 at 8:30 am
Osteoarthritis impacts more than 32.5 million American adults, according to the CDC. New research published in the Proceedings of National Academy of Sciences suggests an innovative machine learning ...
- Osteoarthritis Therapeutics Market Trend Report Offers Market Positioning of Vendors, Drivers and Challenges and Global Forecast 2023on September 29, 2020 at 10:45 pm
Global “ Osteoarthritis Therapeutics Market ” Research Report provides exhaustive analysis of major driving factors, market trends, Osteoarthritis Therapeutics business opportunities, threats and ...
- United States Osteoarthritis Market and Competitive Landscape Report 2020 - ResearchAndMarkets.comon September 29, 2020 at 8:23 am
The "US Osteoarthritis Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
- Pittsburgh Researchers Design Computer Software That Detects Osteoarthritis Before Symptoms Developon September 28, 2020 at 5:31 pm
More than 3 million Americans and almost 25 percent of Pennsylvanians have osteoarthritis, a debilitating joint disease. Currently, there is no cure. Osteoarthritis contributes to the hundreds of ...
- Global Drugs for Osteoarthritis Pain Market 2020 Development Analysis, Strategic Outlook, Growth Rate and Forecast to 2025on September 28, 2020 at 12:39 pm
MarketQuest.biz has titled a new research report named Global Drugs for Osteoarthritis Pain Market 2020 by Company, Regions, Type and Application, Forecast to 2025 to its consistently extending ...
via Bing News